PBT2

DRUG3 trials

Sponsors

Prana Biotechnology Limited

Conditions

Alzheimer's DiseaseHealthy VolunteersHuntington Disease

Phase 1

Phase 1 Study to Determine the Effects of PBT2 on the Pharmacokinetic Profile of Caffeine

CompletedNCT02109497

Prana Biotechnology LimitedHealthy Volunteers

Start: 2014-05-31End: 2014-07-31Updated: 2016-04-29

Phase 2

Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease

CompletedNCT00471211

Prana Biotechnology LimitedAlzheimer's Disease

Start: 2006-12-31End: 2007-12-31Target: 80Updated: 2008-01-16

Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease

CompletedNCT01590888

Prana Biotechnology LimitedHuntington Disease

Start: 2012-04-30End: 2014-02-28Updated: 2016-07-18

Related Papers

Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.

2014-11-1497 citations

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.

2008-07-30514 citations